Abstract
The amyloid precursor protein (APP) has previously been allocated to an organellar pool residing in the Golgi apparatus and in endosomal compartments, and in its mature form to a presynaptic active zone-localized pool. By analyzing homozygous APP knockout mice we evaluated the impact of APP on synaptic vesicle protein abundance at synaptic release sites. Following immunopurification of synaptic vesicles and the attached presynaptic plasma membrane, individual proteins were subjected to quantitative Western blot analysis. We demonstrate that APP deletion in knockout animals reduces the abundance of the synaptic vesicle proteins synaptophysin, synaptotagmin-1, and SV2A at the presynaptic active zone. Conversely, deletion of the additional APP family members, APLP1 and APLP2 resulted in an increase in synaptophysin, synaptogamin-1, and SV2A abundance. When transmembrane APP is lacking in APPsα-KI/APLP2-KO mice synaptic vesicle protein abundance corresponds to that in APP -KO mice. Deletion of the synaptic vesicle protein 2 (SV2) A and B had no effect on APP and synaptophysin abundance but decreased synaptotagmin-1. Our data suggest that APP controls the abundance of synaptic vesicle proteins at the presynaptic release sites and thus impacts synaptic transmission.
Keywords: Amyloid precursor protein APP, APLP1, APLP2, docked synaptic vesicles, presynaptic active zone, SV2, synaptotagmin- 1, synaptophysin.
Current Alzheimer Research
Title:Amyloid Precursor Protein Knockout Diminishes Synaptic Vesicle Proteins at the Presynaptic Active Zone in Mouse Brain
Volume: 11 Issue: 10
Author(s): Melanie Laßek, Jens Weingarten, Amparo Acker-Palmer, Sandra M. Bajjalieh, Ulrike Muller and Walter Volknandt
Affiliation:
Keywords: Amyloid precursor protein APP, APLP1, APLP2, docked synaptic vesicles, presynaptic active zone, SV2, synaptotagmin- 1, synaptophysin.
Abstract: The amyloid precursor protein (APP) has previously been allocated to an organellar pool residing in the Golgi apparatus and in endosomal compartments, and in its mature form to a presynaptic active zone-localized pool. By analyzing homozygous APP knockout mice we evaluated the impact of APP on synaptic vesicle protein abundance at synaptic release sites. Following immunopurification of synaptic vesicles and the attached presynaptic plasma membrane, individual proteins were subjected to quantitative Western blot analysis. We demonstrate that APP deletion in knockout animals reduces the abundance of the synaptic vesicle proteins synaptophysin, synaptotagmin-1, and SV2A at the presynaptic active zone. Conversely, deletion of the additional APP family members, APLP1 and APLP2 resulted in an increase in synaptophysin, synaptogamin-1, and SV2A abundance. When transmembrane APP is lacking in APPsα-KI/APLP2-KO mice synaptic vesicle protein abundance corresponds to that in APP -KO mice. Deletion of the synaptic vesicle protein 2 (SV2) A and B had no effect on APP and synaptophysin abundance but decreased synaptotagmin-1. Our data suggest that APP controls the abundance of synaptic vesicle proteins at the presynaptic release sites and thus impacts synaptic transmission.
Export Options
About this article
Cite this article as:
Laßek Melanie, Weingarten Jens, Acker-Palmer Amparo, Bajjalieh M. Sandra, Muller Ulrike and Volknandt Walter, Amyloid Precursor Protein Knockout Diminishes Synaptic Vesicle Proteins at the Presynaptic Active Zone in Mouse Brain, Current Alzheimer Research 2014; 11 (10) . https://dx.doi.org/10.2174/1567205011666141107152458
DOI https://dx.doi.org/10.2174/1567205011666141107152458 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MYC-mediated Synthetic Lethality for Treatment of Hematological Malignancies
Current Cancer Drug Targets Modulation of Plasma Non Enzimatic Antioxidant Capacity (NEAC) by Plant Foods: the Role of Polyphenol
Current Topics in Medicinal Chemistry Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review
Current Stem Cell Research & Therapy Current Immunotherapies for Renal Cell Carcinoma
Current Molecular Pharmacology Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Intraocular Inflammation and Systemic Immune-Mediated Diseases
Current Immunology Reviews (Discontinued) Azathioprine in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Estrogen Regulation of Adipose Tissue Functions: Involvement of Estrogen Receptor Isoforms
Infectious Disorders - Drug Targets Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study
Current Alzheimer Research Monoaminergic Receptors as Modulators of the Perivascular Sympathetic and Sensory CGRPergic Outflows
Current Neuropharmacology Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Regulation of Life Span in Model Organisms
Current Genomics Ethical and Social Issues in Pharmacogenomics Testing
Current Pharmaceutical Design Evidence for, and Importance of, cGMP-Independent Mechanisms with NO and NO Donors on Blood Vessels and Platelets
Current Vascular Pharmacology Discussion on Pharmacogenetic Interaction in G6PD Deficiency and Methods to Identify Potential Hemolytic Drugs
Cardiovascular & Hematological Disorders-Drug Targets Decoupling of N-Acetyl-Aspartate and Glutamate Within the Dorsolateral Prefrontal Cortex in Schizophrenia
Current Molecular Medicine Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia
Current Medicinal Chemistry Molecule of the Month
Current Topics in Medicinal Chemistry Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature
Current Topics in Medicinal Chemistry Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction
Current Drug Targets